Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
PRESTWICK CHEMICAL<br />
Boulevard Gonthier d’Andernach<br />
67400 STRASBOURG-Illkirch - FRANCE<br />
Phone: +33 3 69 20 16 00<br />
Fax: +33 3 69 20 16 17<br />
Email: infochem@prestwickchemical.fr<br />
Web site: www.prestwickchemical.com<br />
Contact: Paul BIKARD<br />
Prestwick Chemical is a drug discovery CRO th<strong>at</strong> successfully optimizes your hit<br />
into a clinical candid<strong>at</strong>e. With our premium partners, we offer fully integr<strong>at</strong>ed drug<br />
research: Hit identific<strong>at</strong>ion using smart screening libraries, hit valid<strong>at</strong>ion, hit to lead<br />
expansion, lead optimiz<strong>at</strong>ion and profiling. Our in-house expertise relies on long<br />
term experience in medicinal chemistry, with unprecedented success: 6 compounds<br />
made by Prestwick are currently in clinical development, from Phase I to Phase III. In<br />
l<strong>at</strong>e 2010, one project (developed jointly with Domain Therapeutics) was successfully<br />
licensed to Merck Serono.<br />
PROVEPHARM<br />
45 rue Frédéric Joliot Curie<br />
BP 100 - Technopôle Château Gombert<br />
13013 Marseille - FRANCE<br />
Phone: +33 4 91 11 87 59<br />
Fax: +33 4 91 11 88 11<br />
Email:<br />
christian.neumann@provepharm.com<br />
Web site: www.provepharm.com<br />
Contact: Christian NEUMANN<br />
Thanks to a p<strong>at</strong>ented synthesis p<strong>at</strong>h and genuine scientific work, PROVEPHARM<br />
revamped methylene blue compound as PROVEBLUETM Active Pharmaceutical<br />
Ingredient compliant with all pharmaceutical standards and ICH guidelines, developed<br />
the drug Proveblue Solution for Injection and obtained a centralized marketing<br />
authoriz<strong>at</strong>ion <strong>at</strong> EMA. It is now seeking to introduce the drug in US and to license-out<br />
the use of ProveblueTM API to parties interested in setting up exclusive partnerships<br />
to develop other drugs in well-defined applic<strong>at</strong>ions.<br />
59
Change language